Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

March 31, 2007

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Thalidomide

Trial Locations (20)

13009

Institut Paoli Calmette, Marseille

31059

CHU Purpan, Toulouse

54511

CHU Nancy-Brabois, Vandœuvre-lès-Nancy

59037

CHRU de Lille - Hopital C. Huriez, Lille

75014

Hopital Cochin, Paris

75015

Hopital Necker, Paris

93009

Hopital Avicenne, Bobigny

49 033

CHU d'Angers, Angers

84 000

CH d'Avignon, Avignon

64 100

CH de la Cote Basque, Bayonne

29 609

CHU de Brest - Hopital Morvan, Brest

21 000

CHU Dijon, Dijon

38 043

CHU Albert Michallon, Grenoble

87 042

CHU de Limoges, Limoges

44 093

CHU de Nantes, Nantes

06 202

CHU de Nice - Hopital de l'Archet 1, Nice

75 004

Hotel Dieu, Paris

75 012

Hopital Saint Antoine, Paris

66 046

CH Joffre, Perpignan

76 038

Centre Henry Becquerel, Rouen

All Listed Sponsors
lead

Groupe Francophone des Myelodysplasies

OTHER

NCT00455910 - Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 | Biotech Hunter | Biotech Hunter